Author: claimsbot

1. A liquid electrophotographic ink, comprising:
a non-polar carrier liquid;
pigmented toner particles;
a charge director; and
polymer resin encapsulated metal oxide nanoparticles.
2. The liquid electrophotographic ink as defined in claim 1 wherein each of the polymer resin encapsulated metal oxide nanoparticles includes:
a metal oxide nanoparticle core; and
a polymer resin coating formed on the metal oxide nanoparticle core.
3. The liquid electrophotographic ink as defined in claim 2 wherein the metal oxide nanoparticle core is chosen from zinc oxide, indium tin oxide, zirconium oxide, aluminum oxide, and mixtures thereof.
4. The liquid electrophotographic ink as defined in claim 2 wherein the polymer resin coating is formed of a thermoplastic polymer.
5. The liquid electrophotographic ink as defined in claim 4 wherein the thermoplastic polymer includes COOH surface groups that react with hydroxyl groups of the metal oxide nanoparticle core.
6. The liquid electrophotographic ink as defined in claim 2 wherein each of the polymer encapsulated metal oxide nanoparticles has an average particle size ranging from about 10 nm to about 200 nm.
7. The liquid electrophotographic ink as defined in claim 1 wherein electrical properties of the liquid electrophotographic ink are unaffected by the polymer resin encapsulated metal oxide nanoparticles.
8. The liquid electrophotographic ink as defined in claim 1 wherein the pigmented toner particles include a pigment and a polymer resin associated with the pigment.
9. A method for making a liquid electrophotographic ink, comprising:
mixing a polymer resin with a non-polar carrier liquid to form a mixture;
grinding the mixture with a pigment to form pigmented toner particles in the non-polar carrier liquid;
after the pigmented toner particles are formed, adding a charge director to the non-polar carrier liquid to impart a charge on the pigmented toner particles;
adding metal oxide nanoparticle cores i) during the mixing step, or ii) during the grinding step, or iii) after the pigmented toner particles are formed; and
processing the metal oxide nanoparticle cores and the polymer resin to form polymer resin encapsulated metal oxide nanoparticles.
10. The method as defined in claim 9, further comprising choosing the metal oxide nanoparticle cores from zinc oxide, indium tin oxide, zirconium oxide, and mixtures thereof.
11. The method as defined in claim 9, further comprising incorporating the metal oxide nanoparticle cores in an amount ranging from about 0.5 wt % to about 5 wt % with respect to a total weight of the liquid electrophotographic ink.
12. An ink set, comprising:
at least two inks, each of which includes:
a non-polar carrier liquid;
pigmented toner particles;
a charge director; and
polymer resin encapsulated metal oxide nanoparticles.
13. The ink set as defined in claim 12 wherein each of the polymer resin encapsulated metal oxide nanoparticles includes:
a metal oxide nanoparticle core chosen from zinc oxide, indium tin oxide, zirconium oxide, and mixtures thereof; and
a thermoplastic polymer resin coating formed on the metal oxide nanoparticle core.
14. The ink set as defined in claim 13 wherein the metal oxide nanoparticle core has a hardness greater than a hardness of the thermoplastic polymer resin coating.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

We claim:

1. A patient individualized controlled detoxification treatment method for use by a patient dependent upon an addictive drug comprising:
establishing a primary medical response including stabilizing the patient’s life functions, obtaining the patient’s medical history, and normalizing brain receptor chemistry of the patient to a pre-addictive state over a period of time from about 1 to less than 365 days, by administering to the patient an individually-titrated minimal effective dose of the addictive drug, the addictive drug’s agonist or the addictive drug’s antagonist, via a first drug delivery system that establishes a steady state concentration of said addictive drug, the addictive drug’s agonist or the addictive drug’s antagonist, respectively, which eliminates the patient’s addictive drug’s withdrawal symptoms, and then
reducing said titrated minimal effective dose of said addictive drug, the addictive drug’s agonist or the addictive drug’s antagonist, respectively, administered to the patient in a stepwise decreasing fashion over said time period for effecting a decreasing pharmacological concentration to a placebo level of the addictive drug.
2. The individualized controlled detoxification treatment method of claim 1 further comprising administering to the patient an effective amount of the addictive drug, the addictive drug’s agonist, or the addictive drug’s antagonist, respectively, via a second drug delivery system to control the patient’s periodic addictive drug cravings.
3. The individualized controlled detoxification treatment method of claim 1 including wherein said first drug delivery system is at least one of the systems selected from the group consisting of a transdermal delivery system, an intranasal delivery system, a sublingual delivery system, an oral delivery system, an inhalation delivery system to the respiratory tract, an intravenous injection delivery system to the blood stream, a subcutaneous injection delivery system, and an intramuscular delivery system.
4. The individualized controlled detoxification treatment method of claim 2 including wherein said second drug delivery system is at least one of the systems selected from the group consisting of an intranasal delivery system, a sublingual delivery system, an intravenous injection delivery system to the blood stream, a subcutaneous injection delivery system, and an intramuscular delivery system.
5. The individualized controlled detoxification treatment method of claim 1 further comprising establishing for the patient at least one or a combination of secondary responses selected from the group consisting of individualized psychotherapeutic counseling, behaviorstress modification training, ancillary legal and vocational support services, family support systems, workplace support systems, societal support systems, and long-term booster counseling and medicaldrug follow-up testing.
6. The individualized controlled detoxification treatment method of claim 1, including wherein said addictive drug is at least one selected from the group consisting of opiods, opiod derivatives, stimulants, depressants, cannabinoids, dissociative anesthetics and hallucinogens.
7. The individualized controlled detoxification treatment method of claim 1 including wherein said addictive drug’s agonist is at least one selected from the group consisting of methadone and levomethadyl acetate.
8. The individualized controlled detoxification treatment method of claim 1 including wherein said addictive drug’s antagonist is at least one selected from the group consisting of naloxone and naltrexone.
9. A transdermal drug delivery system for promoting detoxification of a mammal dependent upon an addictive drug comprising:
a transdermal pharmaceutical vehicle, and
a pharmaceutically active effective amount of an addictive drug, the addictive drug’s agonist, or the addictive drug’s antagonist contained within said pharmaceutical vehicle and capable of being released from said transdermal pharmaceutical vehicle over time to prevent drug withdrawal symptoms from occurring in the mammal.
10. The transdermal drug delivery system of claim 9 further comprising an effective amount of at least one of the group consisting of a surfactant, an antioxidant, and a preservative, and combinations thereof.
11. The transdermal drug delivery system of claim 10 wherein said surfactant is a salt of a long chain hydrocarbon with a functional group selected from the group consisting of carboxylates, sulfonates and mixtures thereof, a salt of a long chain hydrocarbon with a sulfate functional group.
12. The transdermal drug delivery system of claim 11 wherein said surfactant is sodium lauryl sulfate.
13. The transdermal drug delivery system of claim 9 capable of maintaining in the mammal a constant blood plasma concentration of said addictive drug, said addictive drug’s agonist, or said addictive drug’s antagonist after administering the transdermal drug delivery system to the skin.
14. The transdermal drug delivery system of claim 9 wherein the amount of addictive drug, addictive drug agonist or addictive drug antagonist is from about 1.0 to 500.0 milligrams.
15. The transdermal drug delivery system of claim 10 having from about 0.1 to 1.0 weight percent of said surfactant.
16. A method of detoxifying a mammal that is dependent upon an addictive drug comprising:
administering to the skin of the mammal a dosage unit comprising a transdermal pharmaceutical vehicle and a pharmaceutically active effective amount of an addictive drug, the addictive drug’s agonist, or the addictive drug’s antagonist contained within said transdermal pharmaceutical vehicle and capable of being released from said transdermal pharmaceutical vehicle over time, to prevent drug withdrawal symptoms from occurring in the mammal.
17. An intranasal drug delivery system for promoting detoxification of a mammal dependent upon an addictive drug comprising:
a pharmaceutical vehicle capable of being administered to the nasal mucosa, and
a pharmaceutically active effective amount of an addictive drug, the addictive drug’s agonist, or the addictive drug’s antagonist incorporated with said pharmaceutical vehicle.
18. The intranasal drug delivery system of claim 17, wherein said system has a pH of about 7.0.
19. The intranasal drug delivery system of claim 17 further comprising an effective amount of at least one of the group consisting of a surfactant, an antioxidant, and a preservative, and combinations thereof.
20. The intranasal drug delivery system of claim 19 wherein said surfactant is a salt of a long chain hydrocarbon with a functional group selected from the group consisting of carboxylates, sulfonates and mixtures thereof or a salt of a long chain hydrocarbon with a sulfate functional group.
21. The intranasal drug delivery system of claim 20 wherein said surfactant is sodium lauryl sulfate.
22. The intranasal drug delivery system of claim 17 capable of maintaining in the mammal a pharmaceutically-active blood plasma concentration of said addictive drug, said addictive drug’s agonist, or said addictive drug’s antagonist after administering the intranasal drug delivery system to the nasal mucosa of the mammal.
23. The intranasal drug delivery system of claim 17 wherein the amount of addictive drug, addictive drug agonist, or addictive drug antagonist is from about 1.0 to 500.0 milligrams.
24. The intranasal drug delivery system of claim 17 having from about 0.1 to 1.0 weight percent of said surfactant.
25. A method of detoxifying a mammal that is dependent upon an addictive drug comprising: administering to the nasal mucosa of the mammal a dosage unit comprising a pharmaceutical vehicle capable of being administered to the nasal mucosa and a pharmaceutically active effective amount of an addictive drug, the addictive drug’s agonist or the addictive drug’s antagonist incorporated with said pharmaceutical vehicle to prevent drug withdrawal symptoms from occurring in the mammal.
26. The intranasal drug delivery system of claim 17 wherein said pharmaceutical vehicle is selected from the group consisting of an aqueous buffered solution, a gel, and a powder.
27. The intranasal drug delivery system of claim 19 wherein said surfactant is an anionic surfactant.
28. A sublingual drug delivery system for promoting detoxification of a mammal dependent upon an addictive drug comprising:
a pharmaceutical vehicle capable of being administered to effect dissolution upon the mammal’s sublingual mucosa, and
a pharmaceutically active effective amount of an addictive drug, the addictive drug’s agonist, the addictive drug’s antagonist incorporated with said pharmaceutical vehicle.
29. The sublingual drug delivery system of claim 28 wherein said system has a pH of about 7.0.
30. The sublingual drug delivery system of claim 28 further comprising an effective amount of at least one of the group consisting of a surfactant, an antioxidant, and a preservative, and combinations thereof.
31. The sublingual drug delivery system of claim 30 wherein said surfactant is a salt of a long chain hydrocarbon with a functional group selected from the group consisting of carboxylates, sulfonates and mixtures thereof, or a salt of a long chain hydrocarbon with sulfate functional group.
32. The sublingual drug delivery system of claim 31 wherein said surfactant is sodium lauryl sulfate.
33. The sublingual drug delivery system of claim 28 capable of maintaining in the mammal a pharmaceutically-active blood plasma concentration of said addictive drug, said addictive drug’s agonist, or said addictive drug’s antagonist after administering the sublingual drug delivery system to the mammal’s sublingual mucosa.
34. The sublingual drug delivery system of claim 28 wherein the amount of addictive drug, addictive drug agonist, or addictive drug antagonist is from about 1.0 to 500.0 milligrams.
35. The sublingual drug delivery system of claim 28 having from about 0.1 to 1.0 weight percent of said surfactant.
36. A method of detoxifying a mammal that is dependent upon an addictive drug comprising:
administering under the tongue of the mammal a dosage unit comprising a pharmaceutical vehicle capable of being administered to effect dissolution upon the mammal’s sublingual mucosa and a pharmaceutically active effective amount of an addictive drug, the addictive drug’s agonist, or the addictive drug’s antagonist incorporated with said pharmaceutical vehicle to prevent drug withdrawal symptoms from occurring in the mammal.
37. The sublingual drug delivery system of claim 28 wherein said pharmaceutical vehicle is an aqueous buffered formulation that begins dissolution upon the mammal’s sublingual mucosa in about 0.01 to 600.0 seconds of time.
38. The sublingual drug delivery system of claim 30, wherein said surfactant is an anionic surfactant.
39. A method for developing a treatment plan for a new patient for purposes of administering various phases of treatment to the new patient comprising the steps of:
collecting information from other patients as treatment is administered;
storing said collected information in a database;
developing trends from other patients’ treatments, based upon said collected information; and
analyzing said trends and applying them to said new patient for purposes of establishing a treatment protocol relative to said new patient.
40. The method of claim 39 including wherein said collected information includes information regarding both treatment and medical outcome.
41. The method of claim 39 including predicting the medical outcome of said new patient.
42. The method of claim 40 including wherein said collected information is dependent upon the current phase of treatment for said patient.
43. The method of claim 39 further comprising the step of recognizing, based upon said trends, when a patient has progressed to a new phase and when said treatment for said patient should be modified.

1. A method for managing an organization’s financial investment in human capital resources, the method comprising:
providing an information processing system comprising a microprocessor for executing programs, a memory operatively connected to said microprocessor, and a program stored in said memory and executable by said microprocessor:

operating the information processing system to:
cause the microprocessor to execute the program to receive as inputted data information gathered from the organization’s financial statements;
cause the microprocessor to execute the program to calculate revenue, material cost, financial capital cost, and human capital cost as a function of the inputted data;
cause the microprocessor to execute the program to determine the organization’s human capital productivity as a function of the organization’s revenues related to human capital costs in relation to the organization’s total human capital costs and financial capital costs for a defined period;
cause the microprocessor to execute the program to determine the organization’s return on human capital as a function of the organization’s income in excess of its financial capital costs in relation to its monetary investment in human capital for the defined period;
determining cause the microprocessor to execute the program to determine the organization’s profit sensitivity as a ratio between budgeted, profit-driven incentive compensation and profit to determine how sensitive the organization’s profitability is to changes in incentive compensation;
cause the microprocessor to execute the program to determine an index value as a weighted sum of the organization’s human capital productivity, return on human capital, and profit sensitivity, the index value providing a single composite measure of the organization’s financial investment in human capital resources;
cause the microprocessor to execute the program to identify a specific value to be adjusted to improve the index value, the specific value being selected from the group consisting of a metric value, an argument used to calculate a metric values, and information used to calculate an argument; and
making a business decision to adjust the specific value, the business decision causing changes in operations of the organization that will necessarily change a calculated value of at least one of revenue, material cost, financial capital cost, and human capital cost, and thereby adjust a calculation of the specific value.
2. The method of claim 1, wherein the program’s determining the organization’s human capital productivity comprises the program’s calculating a human capital productivity (HCP) metric value as
HCP
=
R
–
MC
HCC
+
FCC
where, R is a value representing the organization’s revenue, MC is a value reflecting the organization’s material costs, FCC is a value representing the organizations financial capital costs, and HCC is a value representing the organization’s human capital costs, for a defined period of time;
wherein determining the organization’s return on human capital comprises calculating a return on human capital (ROHC) metric value as
ROHC
=
I
–
FCC

HCC
where, I is a value representing the organization’s Income, FCC is a value representing the organization’s financial capital costs, and HCC is a value representing the organization’s human capital costs, for the defined period of time;
wherein determining the organization’s profit sensitivity comprises calculating a profit sensitivity (PS) metric value as
PS
=

IC

I
C
where, IC is a value representing the organization’s budgeted profit-driven Incentive Compensation, and IC is a value representing an organization-defined Income; and
wherein determining the index value comprises calculating an index value metric as
Index
=
C
1

\u2062

HCP

B
HCP
+
C
2

\u2062

ROHC

B
ROHC
+
C
3

\u2062

PS

B
PS
where C1, C2 and C3 are arbitrary coefficients providing mathematical weighting to each of the HCP, ROHC, and PS metrics, and wherein BHCP, BROHC and BPS are budgeted values for each of HCP, ROHC and PS, respectively.
3. The method of claim 1, further comprising: operating the information processing system to cause the microprocessor to execute the program to prepare a report displaying the calculated index value.
4. The method of claim 3, wherein the report is displayed by a video display device of a computerized device.
5. The method of claim 3, wherein the report is prepared in printed form.
6. The method of claim 2, wherein each of R, MC, I, FCC, HCC and IC is calculated by the program as a function of at least one value identified on a financial statement for the organization.
7. The method of claim 2, wherein HCC is calculated by the program by summing values representing employee costs, costs in support of employees, and costs in lieu of employees for the organization.
8. The method of claim 7, wherein each of employee costs, costs in support of employees and costs in lieu of employees is determined by the program as a function of at least one value identified by a general ledger account of the organization.
9. The method of claim 2, wherein the value representing the organization’s Income for use by the program in calculating the ROHC metric is an EBITDA value of the organization for the defined period of time.
10. The method of claim 2, wherein C1, C2 and C3 provide unequal mathematical weight to each of the factors.
11. A computer-implemented method for analyzing an organization’s financial investment in human capital resources, the method being carried out by an information processing system comprising a microprocessor for executing programs, a memory operatively connected to said microprocessor, and a program stored in said memory and executable by said microprocessor to carry out the method, the method comprising:
receiving information gathered from the organization’s financial statements as inputted data;
calculating, by the information processing system, a human capital productivity (HCP) value as
HCP=(R\u2212MC(HCC+FCC)),

where, R is a value representing the organization’s revenue, MC is a value reflecting the organization’s material costs, FCC is a value representing the organizations financial capital costs, and HCC is a value representing the organization’s human capital costs, for a defined period of time, each of R, MC, FCC and HCC being calculated as a function of the inputted data;

calculating a return on human capital (ROHC) value as
ROHC=(I\u2212FCC)HCC
where, I is a value representing the organization’s Income for the defined period of time, I being calculated as a function of the inputted data;
calculating a profit sensitivity (PS) metric value as
PS=ICIC
where, IC is a value representing the organization’s budgeted profit-driven Incentive Compensation, and IC is a value representing an organization-defined Income;
calculating an index value as
Index=C1(HCPBHCP)+C2(ROHCBROHC)+C3(PSBPS)
where C1, C2, and C3 are arbitrary coefficients providing mathematical weighting to each of the HCP, ROHC, and PS metrics, and wherein BHCP, BROHC and BPS are budgeted values for each of HCP, ROHC and PS respectively;
identifying a specific value to be adjusted to improve the index value, the specific value being selected from the group consisting of a metric value, an argument used to calculate a metric values, and information used to calculate an argument; and
providing a report including a recommendation to adjust the specific value.
12. The method of claim 11, further comprising:
comparing at least one of the calculated HCP metric, ROHC metric, PS metric and Index values for the defined period of time to a corresponding value previously calculated for the organization for a second period of time earlier than the defined period of time.
13. The method of claim 12, further comprising:
identifying at least one contributing factor contributing to a difference between the organization’s values and the comparative data, the contributing factor being selected from the group consisting of the index, the metric values, the arguments used to calculate the metric values, and any financial information used to calculate the arguments; and
preparing a report displaying at least one contributing factor and the index value.
14. The method of claim 12, further comprising:
identifying at least one contributing factor contributing to a difference between the organization’s values and the comparative data, the contributing factor being selected from the group consisting of the index, the metric values, the arguments used to calculate the metric values, and any financial information used to calculate the arguments; and
preparing a report displaying at least one contributing factor, and a recommendation to modify the at least one contributing factor.
15. The method of claim 12, further comprising:
identifying at least one contributing factor contributing to a difference between the organization’s values and the comparative data, the contributing factor being selected from the group consisting of the index, the metric values, the arguments used to calculate the metric values, and any financial information used to calculate the arguments; and
recommending a business decision causing change in a respective value of the contributing factor to improve profitability of the organization.
16. The method of claim 11, further comprising:
making a business decision to cause change in a respective value of the contributing factor as a function of the index, the change tending to result in improvement of the calculated index and thus improved profitability of the organization.
17. The method of claim 13, wherein said contributing factor is identified by its difference by more than a predetermined amount from corresponding comparative data.
18. The method of claim 17, further comprising comparing at least one of the calculated HCP metric, ROHC metric, PS metric and Index values for the defined period of time to comparative data for organizations other than the organization, the comparative data being stored in a memory of a computerized system.
19. The method of claim 18, further comprising:
identifying at least one contributing factor contributing to a difference from the comparative data, the contributing factor being selected from the group consisting of the index, the metric values, the arguments used to calculate the metric values, and any financial information used to calculate the arguments; and
preparing a report displaying at least one of the contributing factor and the index value.
20. The method of claim 19, wherein said contributing factor is identified by its difference by more than a predetermined amount from corresponding comparative data.
21. A non-transitory computer readable medium comprising microprocessor-executable instructions for configuring a computerized device to:
calculate a human capital productivity (HCP) value as
HCP
=
R
–
MC
HCC
+
FCC
where, R is a value representing the an organization’s revenue, MC is a value reflecting the organization’s material costs, FCC is a value representing the organization’s financial capital costs, and HCC is a value representing the organization’s human capital costs, for a defined period of time, each of R, MC, FCC and HCC being calculated as a function of inputted data;

calculate a return on human capital (ROHC) value as
ROHC
=
I
–
FCC

HCC
where, I is a value representing the organization’s Income for the defined period of time, I being calculated as a function of inputted data;

calculate a profit sensitivity (PS) metric value as
PS
=

IC

I
C
where, IC is a value representing the organization’s budgeted profit-driven Incentive Compensation, and IC is a value representing an organization-defined Income; and

calculate an index value as
Index
=
C
1

\u2062

HCP

B
HCP
+
C
2

\u2062

ROHC

B
ROHC
+
C
3

\u2062

PS

B
PS
where C1, C2 and C3 are arbitrary coefficients providing mathematical weighting to HCP, ROHC, and PS, respectively, and wherein BHCP, BROHC and BPS are budgeted values for each of HCP, ROHC and PS, respectively.
22. The non-transitory computer readable medium of claim 21, further comprising microprocessor-executable instructions for configuring a computerized device to:
compare at least one of the calculated HCP metric, ROHC metric, PS metric and Index values for the defined period of time to a corresponding value;
identify at least one contributing factor contributing to a difference between the organization’s values and the comparative data, the contributing factor being selected from the group consisting of the index, the metric values, the arguments used to calculate the metric values, and any financial information used to calculate the arguments; and
prepare a report displaying at least one contributing factor and the index value, the contributing factor being identified by its difference by more than a predetermined amount from corresponding comparative data.
23. An information processing system for performing automated analysis of financial investment in human capital resources, the system comprising:
a microprocessor for executing programs;
a memory operatively connected to said microprocessor;
a first program stored in said memory and executable by said microprocessor to:
calculate a human capital productivity (HCP) value as
HCP
=
R
–
MC
HCC
+
FCC
where, R is a value representing an organization’s revenue, MC is a value reflecting the organization’s material costs, FCC is a value representing the organization’s financial capital costs, and HCC is a value representing the organization’s human capital costs, for a defined period of time, each of R, MC, FCC and HCC being calculated as a function of inputted data;

calculate a return on human capital (ROHC) value as
ROHC
=
I
–
FCC

HCC
where, I is a value representing the organization’s Income for the defined period of time, I being calculated as a function of inputted data;

calculate a profit sensitivity (PS) metric value as
PS
=

IC

I
C
where, IC is a value representing the organization’s budgeted profit-driven Incentive Compensation, and IC is a value representing an organization-defined Income; and

calculate an index value as
Index
=
C
1

\u2062

HCP

B
HCP
+
C
2

\u2062

ROHC

B
ROHC
+
C
3

\u2062

PS

B
PS
where C1, C2 and C3 are arbitrary coefficients providing mathematical weighting to HCP, ROHC, and PS, respectively, and wherein BHCP, BROHC and BPS are budgeted values for each of HCP, ROHC and PS, respectively.
24. The information processing system of claim 23, the first program being stored in said memory and executable by said microprocessor to:
compare at least one of the calculated HCP metric, ROHC metric, PS metric and Index values for the defined period of time to a corresponding value;
identify at least one contributing factor contributing to a difference between the organization’s values and the comparative data, the contributing factor being selected from the group consisting of the index, the metric values, the arguments used to calculate the metric values, and any financial information used to calculate the arguments; and
prepare a report displaying at least one contributing factor and the index value, the contributing factor being identified by its difference by more than a predetermined amount from corresponding comparative data.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An automatic applicator for liquid pharmaceutical preparations, the applicator comprising:
an applicator housing; and
an indication barrel;
wherein the indication barrel contains a dose scale on an external surface, in the form of spirally disposed indication numerals, to indicate the set dose at an inspection window fixed in the applicator housing;
wherein the indication barrel is mounted slidingly, co-axially and lengthwise directly on an external surface of the driving barrel in the applicator housing between two end positions defining a working range of the indication barrel, by a splined coupling comprising a plurality of keys located on the internal surface of the indication barrel and extending more than half of the length of the indication barrel, the longitudinal axis of the keys being arranged parallel to a longitudinal axis of the driving barrel;
wherein the driving barrel is mounted rotatably within the applicator housing and is connected to a driving element in the form of a helical spring and to a mechanism for medicine dose setting that comprises a trigger used in conjunction with the helical spring.
2. The applicator according to claim 1, wherein the keys in the splined coupling are bayonet keys.
3. The applicator according to claim 1, wherein the indication barrel is mounted on the driving barrel with its external surface situated at a predefined distance, greater than zero, from the internal surface of the applicator housing.
4. The Applicator according to claim 1, wherein the driving barrel and the indication barrel are joined by the splined coupling such that there is no friction between the surfaces of the driving and indication barrels.
5. The Applicator according to claim 1, wherein the motion of the indication barrel is a spiral movement against the inspection window in the applicator housing; wherein such movement allows any number of complete rotations of the indication barrel against the applicator housing within the range of the displacement of the indication barrel against the driving barrel.
6. A method for indicating a set dose when using an automatic applicator for insulin liquid pharmaceutical preparations, the method comprising:
rotating and displacing an indication barrel;
wherein the indication barrel contains a dose scale on an external surface, in the form of spirally disposed indication numerals,
wherein the indication barrel is being rotated and displaced to indicate the set dose with respect to an inspection window fixed in the applicator housing;
wherein the indication barrel is mounted slidingly, co-axially and lengthwise directly on an external surface of the driving barrel in the applicator housing between two end positions defining a working range of the indication barrel by a splined coupling such that there is clearance between the external wall of the driving barrel and the internal wall of the indication barrel;
wherein the indication barrel can be rotated and displaced within the working range over a plurality of rotations with respect to the applicator housing;
wherein the working range of the indication barrel is within the housing;
wherein the splined coupling comprises a plurality of keys located on the internal surface of the indication barrel and extending more than half of the length of the indication barrel, the longitudinal axis of the keys being arranged parallel to a longitudinal axis of the driving barrel;
wherein the driving barrel is mounted rotatably within the applicator housing and is connected to a driving element in the form of a helical spring and to a mechanism for medicine dose setting that comprises a trigger used in conjunction with the helical spring;
wherein the mechanism for medicine dose setting comprises a turning knob, said turning knob is turn-able and substantially axially immovable.
7. The method according to claim 6, wherein the keys in the splined coupling are bayonet keys.
8. The method according to claim 6, wherein the indication barrel is mounted on the driving barrel with its external surface situated at a predefined distance, greater than zero, from the internal surface of the applicator housing.
9. The method according to claim 6, wherein the driving barrel and the indication barrel are joined by the splined coupling such that there is no friction between the surfaces of these driving and indication barrels.
10. The method according to claim 6, wherein the motion of the indication barrel is a spiral movement against the inspection window in the applicator housing; wherein such movement allows any number of complete rotations of the indication barrel against the applicator housing within the range of the displacement of the indication barrel against the driving barrel.
11. An automatic applicator for liquid pharmaceutical preparations, the applicator comprising:
an applicator housing; and
an indication barrel;
wherein the indication barrel contains a dose scale on an external surface, in the form of spirally disposed indication numerals, to indicate the set dose at an inspection window fixed in the applicator housing;
wherein the indication barrel is mounted slidingly, co-axially and lengthwise directly on an external surface of the driving barrel in the applicator housing between two end positions defining a working range of the indication barrel by a splined coupling such that there is clearance between the external wall of the driving barrel and the internal wall of the indication barrel;
wherein the working range of the indication barrel is within the applicator housing and comprises a plurality of rotations with respect to the applicator housing;
wherein the splined coupling comprises a plurality of keys located on the internal surface of the indication barrel and extending more than half of the length of the indication barrel, the longitudinal axis of the keys being arranged parallel to a longitudinal axis of the driving barrel and disposed such that the indication barrel and the driving barrel are maintained in the central point of rotation and coaxially with the longitudinal axis of the housing;
wherein the driving barrel is mounted rotatably within the applicator housing and is connected to a driving element in the form of a helical spring and to a mechanism for medicine dose setting that comprises a trigger used in conjunction with the helical spring.
12. The applicator according to claim 11, wherein the keys in the splined coupling are bayonet keys.
13. The applicator according to claim 11, wherein the indication barrel is mounted on the driving barrel with its external surface situated at a predefined distance, greater than zero, from the internal surface of the applicator housing.
14. The Applicator according to claim 11, wherein the driving barrel and the indication barrel are joined by the splined coupling such that there is no friction between the surfaces of the driving and indication barrels.
15. The Applicator according to claim 11, wherein the motion of the indication barrel is a spiral movement against the inspection window in the applicator housing; wherein such movement allows any number of complete rotations of the indication barrel against the applicator housing within the range of the displacement of the indication barrel against the driving barrel.